^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AB598

    i
    Other names: AB598, AB-598, AB 598
    Associations

    News

    Trials
    Company:
    Arcus Biosci
    Drug class:
    CD39 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=81, Recruiting, Arcus Biosciences, Inc. | Trial completion date: Nov 2025 --> Aug 2025 | Trial primary completion date: Nov 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    10ms
    Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=81, Recruiting, Arcus Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    12ms
    Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=81, Not yet recruiting, Arcus Biosciences, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    over1year
    AB598, a therapeutic anti-human CD39 antibody, binds and inhibits CD39 enzymatic activity in vivo to promote anti-tumor immunity (SITC 2022)
    Results Real-time measurement of ATP showed the ability of oxaliplatin to induce ATP release in MC38 tumor cells in vitro . Relative percentages of the immune cells in the lymph nodes were unaffected, suggesting internalization or downregulation, not cellular depletion, as the mechanism for the decrease in cell-surface CD39. Conclusions Our results indicate the superb ability of AB598 to inhibit enzymatic activity and tumor growth in vivo and provide a rationale for the combination of CD39 inhibition with ICD-inducing chemotherapy in the clinic.
    Preclinical • IO biomarker
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    oxaliplatin • AB598